ArticleBMC musculoskeletal disorders2025
The fate of bone marrow edema after core decompression and bone marrow aspiration concentrate grafting for the hip.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBone marrow edema (BME) of the femoral head is a prevalent condition that can cause hip pain and is observed in patients as a standalone finding or in conjunction with degenerative or inflammatory conditions. There has been a lack of extensive study on the effectiveness of combining surgery with biological treatment for BME. The objective of this study was to evaluate the efficiency of core decompression (CD) with bone marrow aspirate concentrate (BMAC) augmentation in alleviating pain and enhancing the quality of life in patients with BME in the hip. MATERIALS AND
methodsWe conducted a retrospective analysis of patients who underwent treatment for BME of the hip using CD combined with BMAC between June 2021 and July 2023. Inclusion criteria consisted of patients diagnosed with BME in the hip (presence of BME on T2-weighted MRI in the femoral head or neck with pain corresponding to the same compartment as the BME). The patients' demographic information, presence of other medical conditions, body mass index (BMI), etiology, and assessments using the visual analog scale (VAS) and Harris hip score (HHS) were recorded. Pre- and postoperative radiographic imaging (XR) and magnetic resonance imaging (MRI) were analyzed.
resultsThis study included 28 patients (40 femoral heads) who underwent CD with BMAC grafting at our institution. Among these patients, 9 had normal or non-diagnostic radiographs, 11 were at ARCO stage Ⅰ, and 8 were at ARCO stage Ⅱ. The mean age at the time of operation was 45.21 years (SD 13.17, range 21-75), and the mean BMI was 24.61 (SD 3.75, range 16.6-32.05). The area of BME showed a significant decrease from 954.21 ± 224.68 mm
conclusionTreatment of BME of the hip using CD combined with BMAC is effective and provides short-term pain relief for BME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.